TrialJournal of neuro-oncology2019

Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.

Sied Kebir et al.PubMed ↗Publisher ↗

No numbers read from the abstract.